On March 3rd, 2023, the signing ceremony for major pharmaceutical and healthcare industry projects in Changping District, Beijing was held at the Zhongguancun Life Science Park. With the theme of “Meeting at Life Valley, Fighting for a Prosperous New Year”, more than ten companies signed major pharmaceutical and healthcare industry projects with the Changping District government on site at the event. Among them, Baheal Pharma Group signed a strategic cooperation agreement with the Changping District government to accelerate the construction of the innovative in vitro diagnostic reagent research and development and production platform. Representatives from more than ten bio-pharmaceutical companies, including Changping District leaders and the President of Baheal Pharma Group, Song Qing, attended the signing ceremony.
Signing ceremony for major pharmaceutical and healthcare industry projects in Changping District
Tarcine BioMed Inc., Beijing(referred to as “Tarcine Biomed”) is a subsidiary of Baheal Biodiagnostics which is under Baheal Pharma Group. As an immunological research and production platform, Tarcine Biomed is mainly engaged in the development and industrialization of early warning and early diagnosis technologies for major human diseases, with a complete system and experience in IVD product declaration, production, and sales. In order to further meet the needs of industrial development, Tarcine Biomed will expand its innovative in vitro diagnostic reagent R&D and transformation base in Changping District. After the base is completed, it will work with several domestic universities and scientific research institutions to achieve rapid transformation of independent innovative in vitro diagnostic reagent research results, allowing more innovative diagnostic reagent projects to land in Changping District and jointly promote the high-quality development of the pharmaceutical and healthcare industry in Changping District. Changping District will provide guarantees and create conditions for industrial project landing and scientific and technological project application.
The relevant officials from Changping District introduced at the signing ceremony that, in recent years, the municipal party committee and the municipal government have attached great importance to the development of the pharmaceutical and healthcare industry in Changping District. It is clearly stated that Changping will build a “Life Valley” with global leading level and create a pharmaceutical and healthcare industry development highland with global competitiveness. “According to the functional positioning requirements given by the Municipal Party Committee and the Municipal Government, relying on regional innovation resources, we comprehensively launch the Pharmaceutical and Healthcare Industry Double-Increase Action Plan, focusing on the “three main tracks” of bio-pharmaceutical cutting-edge technologies, medical devices, and beauty and health, and we plan to achieve the goal of “tripling the three” by the end of the “14th Five-Year Plan” period, and create a more large-scale, higher quality, and more beneficial hundred-billion-level industrial cluster.”
Signing ceremony site
Song Qing, President of Baheal Pharma Group, expressed her gratitude to the Changping District Party Committee and Government for their help and support. She stated that Baheal Pharma Group will take this strategic cooperation agreement as an opportunity to fully promote every aspect of project construction and strive to create a benchmark for high-end independent innovation in vitro diagnostic reagent transformation and industrialization in Changping District.
In recent years, under the strategic guidance of national scientific and technological innovation, innovative achievements in the pharmaceutical and healthcare fields are accelerating their transformation and implementation. As a health industry group driven by technological innovation, Baheal Pharma Group focuses on three major tracks: innovative drugs, high-end medical devices, and technology transformation platforms. Through resource integration and innovation incubation capabilities, they explore original innovation and work together with national-level scientific research institutes to promote the transformation of research results and cultivate and incubate innovative products that truly have clinical application value.
Currently, Baheal Pharma Group has made positive progress in such innovative fields as artificial hearts, medical linear accelerators, medical high-definition endoscopes, medical artificial intelligence, innovative drugs for cancer and bone regeneration, and high-end sustained-release formulations in the healthcare industry, and has established research and development achievement transformation bases and medical intelligent manufacturing industrialization bases in Beijing and Qingdao respectively. In the future, Baheal Pharma Group will continue to promote the transformation and implementation of medical technology products and solutions with independent intellectual property rights in China, and continuously contribute to the development of China’s health industry.
Baheal Medical New Retail Business: Cute Camel Store 2.0 Opened in Qingdao2021-03-20
BAHEAL Pharmaceutical Group Accepted by International Federation of Pharmaceutical Wholesalers2016-04-05
China's first fully magnetically levitated artificial heart is launched, and the layout of the high precision medical track of Baheal Investment enters the harvest period2021-11-26
Baheal Medical Inc. Lands on ChiNext Board Today!2021-06-30
Baheal Medical’s collaboration with Astellas China again to promote commercialization of therapeutic drugs in the urology field2021-11-09
Baheal Receives Four Honors at China Future Healthcare Rankings Top 1002021-04-17
Updated cooperation between Baheal and Itochu witnesses the expanded economic cooperation between Chinese and Japanese companies in Shandong2019-03-29
Baheal Medical Launches Commercialization Platform of Efficacious Cosmetics2021-05-13